APA (7th ed.) Citation

AR, L., SB, J., HW, K., SW, Y., YJ, B., SY, L., . . . JH, N. (2025). A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects. Frontiers in immunology, 16, 1665998. https://doi.org/10.3389/fimmu.2025.1665998

Chicago Style (17th ed.) Citation

AR, Lee, et al. "A20 MRNA Therapeutics Ameliorate Systemic Sclerosis by Suppressing TRAF-6/NF-KB Signaling and DREAM Expression and Exerting Antifibrotic Effects." Frontiers in Immunology 16 (2025): 1665998. https://doi.org/10.3389/fimmu.2025.1665998.

MLA (9th ed.) Citation

AR, Lee, et al. "A20 MRNA Therapeutics Ameliorate Systemic Sclerosis by Suppressing TRAF-6/NF-KB Signaling and DREAM Expression and Exerting Antifibrotic Effects." Frontiers in Immunology, vol. 16, 2025, p. 1665998, https://doi.org/10.3389/fimmu.2025.1665998.